Is Moderna Stock a Buy?
The Motley Fool
Moderna's COVID-19 vaccine sales have declined, but the company has made progress with other products like an RSV vaccine and a combined COVID/flu vaccine. Its pipeline also includes promising candidates for CMV, norovirus, and personalized cancer treatments. Despite the stock's decline, the author believes Moderna is undervalued and has significant upside potential for patient investors.
Continue Reading